E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Treatment of unstable angina/non-ST elevation myocardial infarction |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10028595 |
E.1.2 | Term | Myocardial infarct |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the safety of two dose regimens of adjunctive i.v. UFH (low or standard dose) during PCI in high risk patients with UA/NSTEMI initially treated with s.c. fondaparinux and referred for early coronary angiography |
|
E.2.2 | Secondary objectives of the trial |
To evaluate the net clinical benefit of two dose regimens of adjunctive i.v. UFH (low or standard dose) during PCI in high risk patients with UA/NSTEMI initially treated with s.c. fondaparinux and referred for early coronary angiography. To evaluate the relative efficacy outcomes of two dose regimens of adjunctive i.v. UFH (low or standard dose) during PCI in high risk patients with UA/NSTEMI initially treated with s.c. fondaparinux and referred for early coronary angiography. To evaluate if the bleeding and PCI-related complications associated with adjunctive UFH during PCI in UA/NSTEMI patients initially treated with s.c. fondaparinux is comparable to that observed in OASIS 5 when fondaparinux was used as the sole anticoagulant during PCI |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
ALTRI SOTTOSTUDI: FUTURA:in soggetti con malattia multivascolare per valutare la rivascolarizzazione del solo vaso affetto o la rivascolarizzazione completa.Sottostudio per la valut. di marcatori della coagulazione
|
|
E.3 | Principal inclusion criteria |
1. Presenting or admitted to hospital with symptoms suspected to represent UA or NSTEMI, i.e., clinical history consistent with new onset, or a worsening pattern of, characteristic ischemic chest pain or ischemic symptoms occurring at rest or with minimal activity (lasting longer than 5 minutes or requiring sublingual nitroglycerine for relief of the pain). 2. Available to be enrolled within 48 hours of the onset of the most recent episode of symptoms. 3. Planned coronary angiography, with PCI if indicated, within 72 hours of enrolment where possible. 4. At least two of the three following additional criteria: Age ≥ 60 years Troponin T or I or CK-MB above the upper limit of normal for the local institution; ZM2007/00142/01 CONFIDENTIAL AR1108888 ECG changes compatible with ischemia, i.e., ST depression at least 1 mm in 2 contiguous leads or T wave inversion > 3 mm or any dynamic ST shift or transient ST elevation. 5. Written informed consent dated and signed Following angiography and confirmation that the subject is to undergo PCI, the subject must also meet all of the following additional criteria in order to be randomised: Subjects will have received at least 1 dose of open-label fondaparinux The most recent dose of open-label fondaparinux will not have been more than 24 hours before the start of the PCI procedure. Subjects who present in the catheterization laboratory and who are receiving commercially available fondaparinux prescribed for the initial treatment of UA/NSTEMI, may be considered for randomization if the following additional criteria also apply: Fondaparinux must have approval by the appropriate Regulatory Authority for the treatment of patients with UA/NSTEMI and must have been administered to the subject in accordance with the approved prescribing information. The fondaparinux dosing details must be known at the time of randomization (e.g. as a minimum the number of doses and the exact time of administration of the last dose prior to PCI must be available) |
|
E.4 | Principal exclusion criteria |
1.Age < 21 years. 2.Any contraindication to UFH or fondaparinux 3.Contraindication for angiography or PCI at baseline 4.Subjects requiring urgent (<120 minutes) coronary angiography as characterized by those with: refractory or recurrent angina associated with dynamic ST-deviation heart failure life-threatening arrhythmias haemodynamic instability 5.Subjects already receiving treatment with enoxaparin (or other LMWH), bivalirudin or UFH for treatment of the qualifying events unless the last administered (i.v. or s.c.) dose was: &#8805; 8 hours for LMWH &#8805;60 minutes for bivalirudin &#8805;90 minutes for UFH 6.Hemorrhagic stroke within the last 12 months 7.Indication for anti-coagulation other than ACS during the index hospitalization 8.Pregnancy or women of childbearing potential who are not using an effective method of contraception. 9.Co-morbid condition with life expectancy less than 6 months 10.Currently receiving an experimental pharmacological agent 11.Revascularization procedure already performed for the qualifying event. 12.Severe renal insufficiency (i.e., estimated creatinine clearance <20 ml/min) |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Composite of peri-PCI* major bleeding, minor bleeding or major vascular access site complications * Peri-PCI is defined from randomisation up to 48 hours post PCI procedure |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
- same IMP used at different dosage |
|
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 10 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 12 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 1 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 1 |